Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. - Wikidata - awgldk - TriplyDB

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

http://www.wikidata.org/entity/Q30318822

about

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer Management of locally advanced and metastatic colon cancer in elderly patients Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme Molecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 Toxicity Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments Developing a metagenomic view of xenobiotic metabolism Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury Real-time imaging of intestinal bacterial β-glucuronidase activity by hydrolysis of a fluorescent probe IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice.A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors.Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity Understanding and modulating mammalian-microbial communication for improved human health.The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism Interleukin-18 as a target for modulation of irinotecan-induced intestinal toxicity: a step towards a better therapeutic index?: Commentary on Lima-Junior et al., Br J Pharmacol 171: 2335-2350 Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile.Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats.Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats.Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer.Risk factors associated with Clostridium difficile infection in adult oncology patients.Curcuminoids from Curcuma longaL. reduced intestinal mucositis induced by 5-fluorouracil in mice: Bioadhesive, proliferative, anti-inflammatory and antioxidant effects.

P2860

Q26750190-A9CC5A78-98B2-4CA5-97D0-A10F081C9039 Q26795509-4A2F6E6C-77D8-4920-814F-963845027332 Q27026129-F65C51F7-75E3-492C-B844-18DAA43EA58D Q27314587-5461A2DA-2B87-4F0B-AC9E-762F19612A99 Q27665609-8C432773-A1EB-4F8B-9DBA-5B625EECD0D7 Q27678202-8711A708-FDE5-4E73-B05B-606B71178545 Q28079705-B6C94416-B7A0-4924-A05B-9C8EDA3F51BC Q28273307-3FE34AD9-3BE4-4A98-A9D0-20B71931F78E Q30101057-4D73CCDF-26A2-4BE4-9881-6F4C6C18AABD Q33418086-0D3B9820-2317-4BCC-B867-735D27520892 Q33774917-FACF6C70-194B-480B-980A-273165041499 Q33784710-1B16EB61-0B3E-4568-92BE-2AB94AD570B1 Q33830896-A254B39D-DA03-4957-8F51-D542B9F7BD92 Q33923975-7686CB71-AE51-4D15-BCAD-3B4DDFD57512 Q34246678-0265E77B-CB51-4B21-AEBC-4FF621FFD5A8 Q34484362-F2E2503A-6E69-42D0-A896-B2C57D58BDF1 Q34493889-F351B51D-746F-409A-8D5E-A8D9EDBD62D8 Q35026463-462E74F7-FA4A-47F9-AB64-BD69FB909914 Q35955534-6099F94E-564A-4260-AEB4-F166DAD22A8D Q36124242-1573D0F5-C174-4883-B294-B25A43950157 Q36322815-346BCE48-9C26-4876-8763-9B4D8E5B8FF7 Q36356001-6C318323-73AF-417C-B087-C91F70CAB6B0 Q36411753-A7266DAC-4F7A-48C8-AE75-FA8E30A28CF1 Q36854015-AEDE0EFA-A7E5-4D04-AF87-8C0E753167EB Q36976986-98C18479-363F-4C9F-B0A6-0D69BF0B71F8 Q37607371-88CB82EB-1CE4-42A1-BA99-9BF7B96AC68C Q37630186-5C051E0D-292B-448D-82EB-81EB441C97C6 Q38166233-A14913AE-0752-41BD-9AF6-E694644CCE7E Q38183359-C416968A-AAED-46DD-9D39-DB897B4C8153 Q38376098-421A60B0-F08C-4B94-8E3C-0F8AF7EE6559 Q38589005-D651CDF3-4C5A-40B8-9153-29AA6754DE38 Q38922471-3DB006E9-8CF6-411C-B650-D966A5CB7772 Q38945299-6E60433F-5F9A-4514-A815-58936BA0CE5B Q38973323-0DFA49DC-F31B-49A0-BD1B-80F5407403E1 Q39139284-A89F8130-6614-4BE9-9718-CE289D1E7521 Q39433738-28A28959-0BE3-483B-95AE-4CE77C51795F Q41160069-BB465B65-99FD-4BCE-AE60-87918E2B4FFC Q41623664-AA2CA8D8-6C56-4137-A2C4-FF83E39D00D3 Q41655888-A70AD18D-F297-49D3-983B-CF67A9CB7B5C Q41679852-6FD5CCAC-B83C-465B-90E5-38DE1C1C8EAF

P2860

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

http://www.wikidata.org/entity/Q30318822

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

@ast

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

@en

type

label

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

@ast

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

@en

prefLabel

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

@ast

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

@en

P1433

Q30318822-B20DD8A8-9018-4AE6-AA89-A74D3202D733

P1476

Q30318822-9FD8EC66-EA79-4EB2-A281-0065E4FA9058

P2093

Q30318822-5D0C16D6-02D7-407F-895F-A229DB0E9F6E

Q30318822-DB52B0C5-A0D8-430B-952B-A71E7E9CD1F5

Q30318822-EA595478-2C79-4074-BF85-51F0D965A230

P2860

Q30318822-05E6BC2F-61AF-47D0-A2B8-FFB47F388E49

Q30318822-09D7536D-0D96-4865-93E1-F589E86187C3

Q30318822-0BB26D97-2E16-49A9-9F5E-38FF1C9A0F17

Q30318822-0D24E048-D2EF-4081-AC40-1CD45C699FB4

Q30318822-10432223-90B9-4EE5-8997-9FDE072ABBF1

Q30318822-11BDEDD8-727F-480A-9479-B57AF268C396

Q30318822-126C03F4-494B-4BF4-9CC5-7615736E9DB3

Q30318822-14676DB6-85B2-4BE9-884C-0068AA446E7A

Q30318822-189A42B0-0C85-447A-991F-EC1BFF7C5778

Q30318822-2195CF21-4BE1-4D4D-862A-896FE6E5F46E

P304

Q30318822-4CC34827-9C3C-400C-8D84-76F79D14D3F8

P31

Q30318822-EB08991D-3637-4E19-903A-82A90893117C

P356

Q30318822-0A1A487E-EDE6-4159-93C3-994E310FE9FD

P433

Q30318822-05A31362-7BE7-4253-9D23-5B6B5661CD39

P478

Q30318822-C52CFBDA-8D6D-4348-8FEC-9A2316447FE9

P577

Q30318822-2C2B0208-69C5-4CBB-9C9F-9BAAF8B8E48C

P5875

Q30318822-D31D8A4C-A36D-4CD5-BCFD-E0E7AE83619D

P698

Q30318822-900B0D37-BE6F-4F9B-A311-9CBBFF2E1A03

P921

Q30318822-26C1D5F9-BA24-48D6-A864-867626C46D53

Q30318822-4515FD52-81E9-488D-8065-CA5DBA9F0321

Q30318822-D2616D2F-C187-4A6D-8639-1FF0A76E0B59

P932

Q30318822-35873BAD-4580-4F8E-BC7C-C37CC45432E0

P356

1758834009355164

P1433

Therapeutic advances in medical oncology

P1476

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

@en

P2093

Alexander Stein

http://www.w3.org/2001/XMLSchema#string

Karin Jordan

http://www.w3.org/2001/XMLSchema#string

Wieland Voigt

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Sorafenib in advanced hepatocellular carcinoma

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

P304

51-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834009355164

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51521166

http://www.w3.org/2001/XMLSchema#string

P698

21789126

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

Afọ ọsịsa

P932

3126005

http://www.w3.org/2001/XMLSchema#string